Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab

  • John Fredy Nieto-Ríos Sección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, Medellín
  • Arbey Aristizabal-Alzate Sección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, Medellín
  • Catalina Ocampo-Kohn Sección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, Medellín
  • Juan José Vanegas-Ruiz Sección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, Medellín
  • Catalina Vélez-Echeverri Sección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, Medellín
  • Lina María Serna-Higuita Sección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, Medellín
  • Daniel Camilo Aguirre Instituto de Investigaciones Médicas, Universidad de Antioquia, Antioquía
  • Carlos Enrique Yepes-Delgado Sección de investigación, Hospital Pablo Tobón Uribe, Medellín
  • Gustavo Zuluaga-Valencia Sección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, Medellín
Keywords: Post transplant lymphoproliferative disease, PTLD, renal transplant, alemtuzumab

Abstract

Introduction: It is well known that the incidence of malignancy is significantly higher in transplanted patients than in general population. The incidence of lymphoproliferative disease post-transplantation (PTLD) is approximately of 1% to 2% in kidney transplantation recipients. Objective: The main objective of this study was to evaluate the PTLD incidence when monitoring kidney transplanted patients between the years 2005 and 2010. Methods: Kidney transplanted patients’ data was retrospectively taken between the years 2005 to 2010 in order to determine the number of PTLD cases according to the inductor scheme used. Results: 425 patients were transplanted between 2005 and 2010. They received alemtuzumab 76.2%, daclizumab 10.7%, basiliximab 3.6% and thymoglobulin 2.4%. The 7% did not receive antibody induction. During this period 2 cases of PTLD ocurred: One with multiple myeloma and the other with lymphoma. One of them had been treated with alemtuzumab and the other with thymoglobulin. Conclusions: The PTLD incidence in our group, where alemtuzumab was used predominantly as inductor, was very low; this might suggest that alemtuzumab is a medication that does not increase the risk of this kind of neoplasia.

References

Cleper R, Ben Shalom E, Landau D, Weissman I, Krause I, Konen O, et al. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study. Pediatr Transplant. 2012;16(6):619-26.

Jagadeesh D, Woda BA, Draper J, Evens AM. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol. 2012;13(1):122-36.

Ninan MJ, Datta YH. Post-transplant lymphoproliferative disorder presenting as multiple myeloma. Am J Hematol. 2010;85(8):635-7.

Franco A, Jiménez L, Sillero C, Trigueros M, González D, Alcaraz E, et al. [Post-transplant lymphoproliferative disorders in renal transplantation: two decades of experience]. Nefrologia. 2010;30(6):669-75.

Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323(25):1767-9.

Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221-7.

Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep. 2010;12(6):383-94.

Andreone P, Gramenzi A, Lorenzini S, Biselli M, Cursaro C, Pileri S, et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med. 2003;163(17):1997-2004.

Caillard S, Lelong C, Pessione F, Moulin B; French PTLD Working Group. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant. 2006;6(11):2735-42.

Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342(8886-8887):1514-6.

Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation. 1993;56(1):88-96.

Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation. 2005;80(2):193-7.

Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV, et al. Imunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004;4(1):87-93.

Kirk AD, Cherikh WS, Ring M, Burke G, Kaufman D, Knechtle SJ, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7(11):2619-25.

Martín-Gómez MA, Peña M, Cabello M, Burgos D, Gutierrez C, Sola E, et al. Posttransplant lymphoproliferative disease: a series of 23 cases. Transplant Proc. 2006;38(8):2448-50.

Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81(9):1227-33.

Published
2014-01-01
How to Cite
1.
Nieto-Ríos JF, Aristizabal-Alzate A, Ocampo-Kohn C, Vanegas-Ruiz JJ, Vélez-Echeverri C, Serna-Higuita LM, Aguirre DC, Yepes-Delgado CE, Zuluaga-Valencia G. Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab. Rev Nefrol Dial Traspl. [Internet]. 2014Jan.1 [cited 2024Dec.28];34(1):21-6. Available from: http://vps-1689312-x.dattaweb.com/index.php/rndt/article/view/99
Issue
Vol. 34 No. 1 (2014): Ene.-Mar.
Section
Original Article